PTK2 and ovarian cancer: Osterman et al. demonstrated the role of ECM in promoting platinum resistance in ovarian cancer, in which ECM inhibits focal adhesion kinase (FAK), a cytosolic tyrosine kinase activated by matrix and integrin receptors that controls cell motility.